clinical-trials
Akeso Initiates Phase II Trial of TROP2/Nectin-4 Bispecific ADC in Combination with Ivonescimab for NSCLC
Akeso has dosed the first patient in a Phase II clinical trial of its novel bispecific antibody-drug conjugate AK146D1, combined with Ivonescimab, for advanced non-small cell lung cancer (NSCLC).
AS1 NewsSource: prnewswire.com
Akeso, Inc. announced the commencement of its Phase II clinical study (AK146D1-201), involving its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate, AK146D1. The trial also evaluates the combination of AK146D1 with Ivonescimab, an immunotherapy agent. The first patient has been dosed, marking a key step in the development of this targeted therapy for advanced NSCLC. The study aims to assess the efficacy and safety of this novel treatment approach. Akeso's move into Phase II indicates progress in its oncology pipeline, which could impact investor sentiment and market perception of the company's innovative capabilities. The trial's outcomes may influence future treatment options for NSCLC, a leading cause of cancer-related mortality worldwide.
The trial's progress could positively influence market perception of Akeso's oncology pipeline and biotech innovation.